Skip to content
Screener

Bicara Therapeutics BCAX Business Segments — Research

Similar metrics at other companies

Inhibrx Biosciences, Inc. logo
INBXReportable Segment — Other research and development
$2.91M-7.8%
Travere Therapeutics, Inc. logo
TVTXReportable Segment — Other research and development
$4.84M+9.2%
Alto Neuroscience logo
ANROReportable segment — Other research and development
$1.2M+6.1%
Incyte logo
INCYReportable Segment — Other research and development
$0-100%
Inhibrx Biosciences, Inc. logo
INBXReportable Segment — Other Research and Development Expense
$2.91M-7.8%
Veracyte logo
VCYTReportable Segment — Other research and development expenses
$5.46M+201%

Other financials

Income statement

See full
Operating income-$60.2M-44.2%
Net income-$56.2M-52.6%
EPS (diluted)-$0.93-36.8%

Balance sheet

See full
Cash & equivalents$323.5M-30.0%
Total debt$1.4M+144%
Total equity$514.0M+12.0%
Total assets$553.6M+15.8%

Cash flow

See full
Operating cash flow-$37.5M-33.5%
CapEx$60.0K
Free cash flow-$37.6M-33.7%

Valuation

See full
Market cap$1.84B+234%
Enterprise value$1.52B+1,258%

Returns & leverage

See full
Return on equity-32.3%
Debt / equity0.0×
Current ratio13.9×-10.8×

Where this comes from

Reported directly by Bicara Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OtherResearchAndDevelopmentExpense.

The source filing: Bicara Therapeutics’s 10-Q, filed May 11, 2026.

Filed
May 11, 2026, 4:03 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-033429
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Manufacturing and process development$23,208$18,655
Clinical operations and development14,57010,026
Research and development personnel cost and other (including stock-based compensation)9,1215,096
Research601556
Total research and development47,50034,333
General and administrative personnel costs (including stock-based compensation)7,9634,832
Professional fees3,5601,504
Facility costs, IT, office expense and other1,2191,119

Item 1. Financial Statements (Unaudited)

FAQ

What is Bicara Therapeutics's business segments — research?
Bicara Therapeutics (BCAX) reported business segments — research of $601K in Q1 2026.
How has Bicara Therapeutics's business segments — research changed year-over-year?
Bicara Therapeutics's business segments — research increased by 8.1% year-over-year, from $556K to $601K.
What is the long-term trend for Bicara Therapeutics's business segments — research?
Over 2 years (2023 to 2025), Bicara Therapeutics's business segments — research has grown at a 50.1% compound annual growth rate (CAGR), from $1.39M to $3.12M.
What does business segments — research mean?
Refers to the foundational costs associated with early-stage scientific exploration and discovery efforts. This encompasses initial laboratory work and feasibility studies aimed at identifying and validating new therapeutic targets.

Ask your AI about Bicara Therapeutics's business segments — research.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude